CD123 CAR T–cell therapy for relapse or refractory Blastic plasmacytoid dendritic cell neoplasm

CD123 chimeric antigen receptor T cells (CART) therapy for relapse or refractory Blastic plasmacytoid dendritic cell neoplasm

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900022058

Enrollment

Unknown

Registered

2019-03-22

Start date

2019-03-19

Completion date

Unknown

Last updated

2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

relapse or refractory Blastic plasmacytoid dendritic cell neoplasm

Interventions

CD123 car-t treatment group:CD123 car-t treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. The patient or his/her legal guardians must sign a consent form; 2. The patient ages 6 years to 60 years, male or female; 3. By cell morphology and flow cytometry analysis examination diagnosis of patients with Blastic plasmacytoid dendritic cell neoplasm, poor curative effect after standard treatment scheme, a diagnosis of recurrence of refractory Blastic plasmacytoid dendritic cell neoplasm; 4. The patient has lesions which can be measured or evaluated; 5. Main organs seem to be functioning well: Liver function: bilirubin=34.2umol/L; Renal function: Serum creatinine<220umol/L; Lung function: arterial oxygen saturation=95%; Heart function: LVEF=40%; 6. Peripheral venous blood in patients flow smoothly; 7. Karnofsky score=60.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Patients who want to be pregnant in 1 year; 3. Patients who can not use contraception in 1 year; 4. Uncontrolled active infection with in 4 weeks; 5. Active hepatitis B or hepatitis C virus infection; 6. HIV infected patients; 7. Patients with other cancers diagnosised by pathology; 8. Patients with serious autoimmune diseases or immunodeficiency; 9. Patients who suffer from allergies; 10. Patients who have taken part in other clinical tests within 6 weeks; 11. Patients who use systemic steroids before treatment within 4 weeks; 12. Patients who have a history of central nervous system disease; 13. Patients who are addicted to some drugs; 14. Patients who are not allowed to take part in the test(judged by the researchers).

Design outcomes

Primary

Measure	Time frame
The CAR - T cells infusion quantity and rate of transfection;Imaging or bone marrow test results;Disease progression-free survival time;	—

Countries

China

Contacts

Public ContactDeng Qi

Tianjin First Central Hospital

kachydeng@hotmail.com+86 13612055872

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 27, 2026